<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Henrik Zetterberg</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Gothenburg<br>UCL</td>
</tr>
<tr>
<td class="label">Country</td>
<td>Sweden/UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0003-3939-6464" target="_blank">0000-0003-3939-6464</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Biomarkers](/mechanisms/biomarkers-ad), Neurofilament, [Tau](/mechanisms/tau-pathology), [Alpha-synuclein](/mechanisms/alpha-synuclein)</td>
</tr>
</table>
Henrik Zetterberg
Overview
Mermaid diagram (expand to render)
Henrik Zetterberg is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Gothenburg and UCL. Their research focuses on Biomarkers, Neurofilament, [Tau](/proteins/tau), [Alpha-synuclein](/proteins/alpha-synuclein), with particular emphasis on [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease) and ALS. With an h-index of 200, Zetterberg is among the most cited researchers in the neuroscience field["@orcid2026"].
Zetterberg's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and Parkinson's Disease and ALS. Their research group has made significant contributions to the fields of Biomarkers, Neurofilament, [Tau](/proteins/tau), Alpha-synuclein, publishing in high-impact journals including leading neuroscience journals.
Based at University of Gothenburg and UCL, Zetterberg collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/als)
Mechanisms of Interest
- [Biomarkers](/biomarkers)
- Neurofilament
- [Tau](/mechanisms/tau-pathology)
- [Alpha-synuclein](/proteins/alpha-synuclein)
Programmatic Emphasis
Zetterberg's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease and Parkinson's Disease and ALS[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Biomarkers, Neurofilament, Tau, Alpha-synuclein domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[PubMed author search for Henrik Zetterberg](https://pubmed.ncbi.nlm.nih.gov/?term=Henrik+Zetterberg%5BAuthor%5D)[@orcid2026]
[Google Scholar author search for Henrik Zetterberg](https://scholar.google.com/scholar?q=author%3A%22Henrik+Zetterberg%22)[@orcid2026]
[Semantic Scholar profile search for Henrik Zetterberg](https://www.semanticscholar.org/search?q=Henrik+Zetterberg)[@orcid2026]
Recent Research
Recent PubMed-indexed publications (2024-present):
[Exposure-based Interventions for Chronic Pain and Bodily Symptoms: A Special Interest Meeting Report.](https://pubmed.ncbi.nlm.nih.gov/41762768/). Behaviour research and therapy. 2026.
[Impact of Intraoperative Hypotension and Blood Loss on Brain Damage Biomarkers in Metopic Craniosynostosis Surgery.](https://pubmed.ncbi.nlm.nih.gov/40851400/). Journal of neurosurgical anesthesiology. 2026.
[Comparative analysis of plasma p-tau217 immunoassays: challenges for standardization and harmonization.](https://pubmed.ncbi.nlm.nih.gov/41202177/). Clinical chemistry and laboratory medicine. 2026.
[Inflammation, Limbic White Matter Microstructure, and Clinical Symptoms in Retired American Football Players With Repetitive Head Impacts.](https://pubmed.ncbi.nlm.nih.gov/41740080/). Neurology. 2026.
[Non-physiological potassium concentrations in commercial culture media trigger acute seizure-like activity in human iPSC-derived neurons.](https://pubmed.ncbi.nlm.nih.gov/41851180/). Scientific reports. 2026.
[Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform.](https://pubmed.ncbi.nlm.nih.gov/41845424/). Alzheimer's research & therapy. 2026.
Collaborators and Research Network
[Kaj Blennow](/researchers/kaj-blennow), [John Hardy](/researchers/john-hardy)
Institutional Context
Primary institutional links: [University of Gothenburg](/institutions/university-of-gothenburg), [UCL](/institutions/ucl). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Biomarkers, Neurofilament, Tau, Alpha-synuclein signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease and Parkinson's Disease and ALS into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0003-3939-6464](https://orcid.org/0000-0003-3939-6464)
- Google Scholar: [Search for Henrik Zetterberg](https://scholar.google.com/scholar?q=author%3A%22Henrik+Zetterberg%22)
- PubMed: [Author search for Henrik Zetterberg](https://pubmed.ncbi.nlm.nih.gov/?term=Henrik+Zetterberg%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
Unknown, ORCID profile for Henrik Zetterberg (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)